Fig. 3From: Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfaForest plots of the effects of PAG versus AG in terms of PFS and OS by C3M/PRO-C3 ratio subgroups in Stage 1 and Stage 2 of HALO 109-202. In Stage 1, C3M/PRO-C3 ratio subgroups for PFS analysis were defined by median cut-off and ROC cut-off. In Stage 2, C3M/PRO-C3 ratio subgroups for PFS and OS analyses were defined by median cut-off derived from Stage 1 and ROC cut-off derived from Stage 1. Both median and ROC cut-offs for C3M/PRO-C3 ratio predicted a statistically significant benefit (P < .05) in PFS (Stage 1 and Stage 2) and OS (Stage 2) for PAG vs AG. †ROC cut-off point from Stage 1 for the low biomarker subgroup was < 0.702. ‡ROC cut-off point from Stage 1 for the high biomarker subgroup was ≥ 0.702Back to article page